e11037 Background: ABC is currently an incurable disease but some patients achieve a longer survival. The following case-control study compared patients suffering from ABC that survived 50 months or more after the onset of metastasis (case) with a group of patients similarly diagnosed treated alongside the case group, whose survival after metastasis was less than 50 months (control). Methods: A search of the IOHM breast cancer tumors registry between September 1997 and April 2010 was carried out. Only those with ABC were included in the paper. The population was divided between cases and controls and both groups were compared. Results: 227 patients meeting the required criteria were found. The population characteristics are detailed in the table below. In 161 pts (70%), a molecular subtype was established: Luminal Type A or B (Cases: 49 pts; Controls: 84 pts), Her2 (Cases: 5 pts; Controls: 9 pts), Triple Negative (Cases: 0 pts; Controls: 14 pts). Systemic and local treatments were similar in both groups, depending on the disease’s stage. Conclusions: 1 – Sixty seven patients (cases) survived 50 or more months after the onset of metastasis. 2 – The Luminal Subtype, long DFS of early stages, compromise of non-visceral organs and the compromise of only one organ were indicative of extended survival of the patients. 3 – No patient with Triple Negative tumors was able to achieve prolonged survival, and so we must continue to research better treatments for these patients. [Table: see text]
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.